The anti-PD-L1 monoclonal antibody sugemalimab showed an ORR of 46.2% and a CR rate of 30.4% in a single-arm phase II trial with 80 patients with r/r NKTCL. The gene discussed is CD274; the disease is extranodal nasal NK/T cell lymphoma.